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Abstract
Background: Pseudomonas aeruginosa is a common opportunistic pathogen that causes nosocomial infection in immunocompro-
mised patients. Among different virulence factors, the type III secretion system (TTSS) is an important agent in virulence and devel-
opment of antimicrobial resistance in P. aeruginosa.
Objectives: Previous studies have shown that production of type III secretion system proteins was correlated with increasing viru-
lence and resistance to several antibiotics. In this study we determined the exotoxins genes (exoU and exoS) and pattern of antimi-
crobial susceptibility in clinical P. aeruginosa isolates.
Methods: A total of 175 P. aeruginosa isolates were collected from patients hospitalized in educational hospitals of Shahrekord and
Chamran hospital of Isfahan, Iran from April to December 2015. Antimicrobial susceptibility test was performed by disk diffusion
test. The presence of exotoxins genes was detected using multiplex PCR of exoU and exoS genes.
Results: The antibiotic resistance rate was higher than 70% to many antibiotics. The highest rate of resistance was related to Lev-
ofloxacin and Meropenem (155 (88.6%), 148 (84.6%)) respectively. The exoU gene was found in 75 (42.9%) isolates and 136 (77.7%) of
the isolates carried the exoS. In addition, 36(20.6%) of the isolates carried the both of gens. A statistical significance was detected
between the presence of exoU gene and resistance to pipracillin (P = 0.01).
Conclusions: The result of this study was indicated a high resistance rate to the most antibiotic classes and a specific relationship
between the virulence genotype and antimicrobial resistance especially more virulent genotype of exoU+. In order to prevent the
spread of more virulent strains in health care facilities, molecular methods alongside antimicrobial susceptibility tests is suggested.
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1. Background
Pseudomonas aeruginosa is a Gram- negative and an op-
portunistic pathogen which grow in minimal nutritional
requirements and a wide range of temperature. It can
grow on most of surfaces, especially moist surfaces such
as medical devices and skin (1, 2). Pseudomonas aeruginosa
in weakened and immunosuppressed patients, who are
with third- degree burns, cystic fibrosis (CF), wounds, in-
dwelling catheter and prolonged duration of ventilation
it can cause nosocomial diseases (3). Multiple factors are
involved in pathogenicity of P. aeruginosa. The type III se-
cretion system (TTSS) has been known to be a major vir-
ulence, which is determined in pathogenesis of acute in-
fection, bacteremia, sepsis and subsequent mortality. The
TTSS allows the injection of toxins into the cytosol of target
eukaryotic cells, where they destroy host cell defense and
signaling systems and that subsequently rapid call necro-
sis or modulating the actin cytoskeleton (4-6). Four effec-
tor proteins have been identified: ExoU, which is a phos-
pholipase and it has been characterized as a major viru-
lence factor in acute lung injury, ExoY that is an adenylate
cyclase, and ExoS and ExoT which are bifunctional proteins
(5, 6). ExoU and ExoS are present variably and in patho-
genesis are important, whereas the almost of isolates, ExoT
and ExoY encode and have a minor effect on virulence (4,
5). Previous studies have shown that production of ExoU
was correlated with increasing virulence (7). Other studies
were found that the infected patients with TTSS+ isolates
show more severe infections and the mortality rate of this
patients in first 30 days of infection is high (3, 8). The ex-
istence many of agents in P. aeruginosa leads to intrinsic
resistance to many antimicrobials including bacterium’s
outer membrane barrier, the presence of multi drug eﬄux
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trans-porters and endogenous antimicrobial inactivation.
The all of this agents, also inappropriate chemotherapy
and lagging in antibiotic discovery was caused “antibiotic
resistance crisis” (6, 9). The previous studies were showed
that the inappropriate chemotherapy leads to emerge of
the multi-drug resistant isolates (10), especially in burn
patients, the rate of resistance to most of antibiotics for
P. aeruginosa isolated was reported higher than 70% (11),
However, the ExoU+ isolates are more resistance to floro-
quinolons (12).
2. Objectives
The aim of this study was identification of antimicro-
bial susceptibility pattern and characterization the pres-
ence of exoS and exoU genes in clinically isolated P. aerug-
inosa strains. An improved understanding of these viru-
lence factors is important for selection cure pathway and
suitable antibiotic.
3. Methods
3.1. Isolation and Identification of Bacteria
In a descriptive study which is approved by the
ethics committee of Shahrekord University of Medical sci-
ences (research project number 2450), a total of 175 non-
replicated P. aeruginosa isolates were collected from April
to December 2015 at teaching hospitals of Shahrekord Uni-
versity of Medical Sciences and Chamran hospital of Isfa-
han, Iran. These isolates derived from routine diagnos-
tic tasks and different specimens including wound, blood,
urine, specimens respiratory, burn wound, (cerbrospinal
fluid) CSF and others. After transporting the isolates to
Shahrekord University of Medical microbiology labora-
tory, the isolates were identified as P. aeruginosa by con-
ventional methods (Gram staining, catalase, oxidase, non-
fermentation in (oxidative fermentation) OF culture and
production of pigmentation) (13).
3.2. Antibiotic Susceptibility Test
Antibiotic susceptibility testing of the isolates was per-
formed using Kirby-Bauer disk diffusion method accord-
ing to clinical and laboratory standard institute guide-
line (CLSI, 2015) (14). The tested antimicrobial agents
were as followed: Imipenem (10 µg), Meropenem (10
µg), Doripenem (10µg), Levofloxacin (5µg), Ciprofloxacin
(5 µg), Ceftazidime (30 µg), Cefepime (30 µg), Col-
istin (10 µg), Polymyxin B (30 µg), Gentamicin (10 µg),
Amikacin (30 µg), Tobramycin (10 µg), Pipracillin (100
µg), Pipracillin/Tazobactam (100/10 µg), and Aztreonam
(30 µg) (MAST, Group Ltd, Merseyside, UK). Escherchia coli:
ATCC25922 and P. aeruginosa: ATCC27853 were used as qual-
ity control (CLSI, 2015).
3.3. DNA Extraction
DNA extraction was performed by boiling method with
some modification. An aliquot of 1 mL of the culture grown
overnight at 37°C in 100 µl of (Tris EDTA Acid Acetic)TEA
buffer was boiled for 10 minutes at 100°C and immediately
placed in -20˚C for 10 minutes. After centrifugation of bac-
terial suspensions at 13000× g at 4°C for 10 minutes, the
supernatant was collected and DNA template used for poly-
merase chain reaction (PCR) (15).
3.4. Virulence Genotyping Test Using Multiplex PCR
For identification of exoU and exoS genes in P. aerugi-
nosa isolates multiplex polymerase chain reaction (MPCR)
were performed. Two set of primers were used that are
shown in Table 1 (synthesized by Bioneer, Inc. Seoul, South
Korea). MPCR mixture consisted of 1X reaction buffer (50
mM KCl, 10 mM Tris-HCl (pH 9.0)), 2 mM MgCl2, 200µM con-
centration of each of four deoxyribonucleoside triphos-
phates (dNTPs) (Sina Clon Bio Science Co. Tehran, Iran),
0.4µM primers, 5 U of Taq DNA-polymerase (Sina Clon Bio
Science Co. Tehran, Iran) and 50 ng DNA. Amplification was
performed in a T100TM Thermal Cycler (Bio-Rad Laboratory,
Inc. USA) (16). After an initial denaturation step for 5 min-
utes at 94°C, 30 cycles of amplification were performed as
follows: 94°C for 30 seconds, 59°C for 45 seconds, and 72°C
for 45 seconds. The reaction was completed with a final
extension at 72°C for 10 minutes. The Amplified products
were analyzed by 1.5% agarose gel electrophoresis which is
visualized on an ultraviolet illumination.
Statistical package for the social sciences version 22.0
(SPSS Inc., Chicago, IL, USA) was used for statistical analy-
sis. Fisher’s exact test or Chi-squared test was performed in
order to analyze of categorical data. A P value of < 0.05 was
considered statistically significant.
4. Results
The results of antimicrobial susceptibility testing are
shown in Table 2. All of the isolates were susceptible
to colistin and polymyxin B and the most of them was
resistant to Levofloxacin (155 (88.6%)) and Meropenem
(148 (84.6%)). The highest susceptibility was related to
pipracillin/Tazobactam (59 (33.7)) and Amikacin (54 (30.9));
respectively. Multiplex PCR in order to detect of exoS
and exoU genes was performed for all isolates. Gel elec-
trophoresis results of a number of isolates are shown in
Figure 1. All 175 clinical isolates carried exoS, exoU and
exoU/exoS. The exoU gene was found in 75 (42.9%) isolates
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Table 1. Oligonucleotide Primers Used in This Study
Name Primer Sequence References Size of the Amplicon, bp
ExoU-Fa 5’-AGC GTT AGC GAC GTG CGT TTC A-3’
This study 404c
ExoU-Rb 5’-GCG CCG ATC TCG CTG CTA ATG T-3’
ExoS-F 5’-TTC GGG CAG GGC ACG ATA TCC A-3’
This study 240
ExoS-R 5’-TTC CGG TTT GCT TGC CAG GTC G-3’
aForward primer.
cBase pair.
bReverse primer.
and 136 (77.7%) of isolates had exoS gene. Furthermore, 36
(20.6%) of the isolates carried the both of genes. Statistical
analysis has been showed a significant difference between
the presence of exoU gene and resistance to pipracillin (P
= 0.01). However, there was not detected significant differ-
ence between the presence of exotoxin genes and other an-
tibiotic resistance. Frequency of exoU+ and exoU- among
pipracillin-resistant and non-resistant isolates was shown
in Figure 2.
Table 2. The Results of Antimicrobial Susceptibility Testing in P. Aeruginosa Clinical
Isolatesa
Antibiotics Sensitive Intermediate Resistance
Imipenem, 10µg 25 (14.3) 7 (4.0) 143 (81.7)
Meropenem, 10µg 21 (12.0) 6 (3.4) 148 (84.6)
Doripenem, 10µg 29 (16.6) 10 (5.7) 136 (77.7)
Levofloxacin, 5µg 16 (9.1) 4 (2.3) 155 (88.6)
Ciprofloxacin, 5µg 26 (14.9) 6 (3.4) 143 (81.7)
Ceftazidime, 30µg 35 (20.0) 1 (0.6) 139 (79.4)
Cefepime, 30µg 27 (15.4) 9 (5.1) 139 (79.4)
Colistin, 10µg 175 (100) 0 (0.0) 0 (0.0)
Polymyxin B, 30µg 175 (100) 0 (0.0) 0 (0.0)
Gentamicin, 10µg 30 (17.2) 6 (3.4) 139 (79.4)
Amikacin, 30µg 54 (30.9) 13 (7.4) 108 (61.7)
Tobramycin, 10µg 33 (18.9) 1 (0.6) 141 (80.6)
Pipracillin, 100µg 29 (16.6) 51 (29.1) 95 (54.3)
Pipracillin/Tazobactam,
100/10µg
59 (33.7) 46 (26.3) 70 (40.0)
Aztreonam, 30µg 28 (16.0) 18 (10.3) 129 (73.7)
aValues are expressed as No. (%). No, number of strains.
5. Discussion
Among the all pathogenic bacteria, P. aeruginosa con-
tributes to 11% of all nosocomial infections (17). The clini-
cal P. aeruginosa isolates that secret type III proteins (ExoU
and ExoS) show more antimicrobial resistance and asso-
ciate with increase rates of mortality and morbidity (3).
In this study, all of the isolates showed at least one of
the exotoxin and the prevalence of exoU+/exoS-, exoU-/exoS+
and exoU+/ exoS+ clinical isolates were totally 42.9%, 77.7%
and 20.6%; respectively. In the several studies that have
been conducted on P. aeruginosa isolates, the presence of
exotoxin gene has been reported differently. In a study
by Cho et al., 66 carbapenem- resistant P. aeruginosa iso-
lates from different clinical source were investigated and
the prevalence of exoU, exoS and exoU/exoS genes were re-
ported 66.7%, 30.3% and 3%; respectively (5). These find-
ings are contrary to our results. In a study which is con-
ducted by Ferreira et al., all of 32 P. aeroginosa isolates from
patients with bacteremia and ventilator associated pneu-
monia (VAP) carried exoS gene. The exoU gene was ob-
served only in 9.4% of strains and three isolates were pos-
itive for the two effector genes exoU and exoS (9.4 %) (10).
In another study by Mitove and colleagues on P. aerugi-
nosa isolated from patients with CF and nosocomial infec-
tions, the prevalence of exoS and exoU have been reported
62.4 and 30.2%; respectively (18). Similar to our results, in
this study the prevalence of exoU-/exoS+ isolates was more
than the exoU+/exoS- isolates. However, in our study the
prevalence of exoU+/exoS- was higher than those. In the
study by Firuzi- Dalvand et al., the prevalence of exoU and
exoS genes in burn wound P. aeruginosa isolates were re-
ported 76% and 68%; respectively (19). In another study
that was conducted by Agnello et al., the prevalence of
exoU, exoS , exoU/exoS or other exotoxin genes were 38%, 56%
and 8%; respectively (4). Jabalameli et al., were reported
the frequency of exoS, exoU and exoU/exoS in burn isolates
29%, 64.5% and 1%; respectively (20), which their finds was
conducted with ours. In a survey that conducted by Lak-
shmi Priya et al., all of the isolates were carried one of the
exoU, exoS or exoU/exoS genes. The frequency of exoS and
exoU genes has been detected 64% and 23%; respectively
(21). Garey et al. in a survey on P. aeruginosa isolates from
Avicenna J Clin Microb Infec. In Press(In Press):e44802. 3
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Figure 1. Gel Electrophoresis Results of exoU Gene (404 bp) and exoS Gene (240 bp). Lane 1: Negative Control, Lane 6: 100 bp DNA Ladder, Lanes 2, 7, 9, 10 and 11: Isolates with
exoS Gene, Lanes 3, 4, 5 and 8: Isolates with exoU Gene and Lane 12: Positive Control
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Figure 2. Frequency of exoU+ and exoU- among pipracillin-resistant and Non-
resistant isolates
patients with bacteremia reported that the prevalence of
exoS, exoU and exoU/exoS were 70.5%, 24.5% and 1.6%; respec-
tively (22). Wong-Beringer et al. was found that the preva-
lence of exoS and exoU genes in clinical isolates were 62%
and 27% respectively. These findings were near to our re-
sults (12). According to the mentioned studies and com-
pared them with our study, the observed differences in the
prevalence of exoS and exoU genes may be due to the di-
versity in the type of specimen, strain types and geograph-
ical area of survey. Notably, in our study the percent of
exoU+/exoS+ isolates were relatively high (20.6%) compared
to other studies. Even though exoS and exoU genes are lo-
cated in different location in P. aeruginosa genome, the si-
multaneous carriage of both genes less have been reported
(23). A possible explanation is that both of the ExoU and
ExoS proteins are important for P. aeruginosa survival. How-
ever each of them shows different activity in a specific en-
vironment and situation (23, 24). Therefore, the exotoxins
genotype of a clinical isolate may be indicated of particular
environmental reservoir of that isolate.
Many cases of infections due to P. aeruginosa were
hardly cured and also inappropriate chemotherapy was
caused resistance to many of antibiotics (24, 25). The ex-
tensive use of antibiotics such as flouroquinolones can be
effective in creating the multi-drug resistant isolates. In ad-
dition, previous studies were shown that the presence of
the TTSS effector genotypes, especially exoU genotype, cor-
relate with increasing the virulence and resistance to one
or more antibiotics. In a study by Agnello et al., they were
found that the presence of exoU gene was significantly
correlated with flouroquinolones- resistance (4). Wong-
Beringer et al., also found that 92% of exoU+ and 61% of
exoS+ isolates were resistance to flouroquinolones (12). In
other study by Cho et al., a higher ratio of exoU+ strains
were flouroquinolones-resistant than exoS+ strains (P ≤
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0.0001) (5). In surveys that conducted by Maatallah and
et al., and Pena and et al., the presence of exoU gene sig-
nificantly was correlated with multidrug resistance and
ciprofloxacin resistance (23, 26). In present study 81.7% and
88.6% of isolates were resistant to ciprofloxacin and lev-
ofloxacin; respectively. On the contrary to other studies,
there was no correlation between the resistance to flouro-
quinolones and specific virulence genotype. Although,
resistance to Pipracillin significantly was associated with
presence of exoU gene (P = 0.01). One reason for this differ-
ence may be due to a variation of sample type but further
studies should be conducted in order to find out this dif-
ference.
Our study has some limitation such as single center
study with small sample and lack of funds for more experi-
ments such as Clonality analysis. However, since the study
on distribution of TTSS effector genotypes and antibiotic
resistance in our region is very low, further studies, like our
study, are required.
5.1. Conclusion
In use together, the recent overuse of effective an-
tipseudomonal antibiotics has led to increased resistance
in clinical P. aeruginosa isolated. The present results indi-
cate a specific relationship among the presence exotoxin
genes and antibiotic resistance. In order to prevent the
spread of more virulent strains in health care facilities,
molecular assessment alongside antimicrobial suscepti-
bility tests is suggested.
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